The role of mineralocorticoids in the pathogenesis of hypokalemic periodic paralysis.
D000328:Adult; D000450:Aldosterone / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D003900:Desoxycorticosterone / Q000494:pharmacology; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D006929:Hyperaldosteronism / Q000209:etiology* / Q000517:prevention & control; D007008:Hypokalemia / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D008797:Metyrapone / Q000494:pharmacology; D008901:Mineralocorticoids; D010243:Paralysis / Q000209:etiology* / Q000517:prevention & control; D010507:Periodicity; D012964:Sodium / Q000378:metabolism; D013148:Spironolactone / Q000627:therapeutic use
D008901:Mineralocorticoids; D000804:Angiotensin II; D013148:Spironolactone; D003900:Desoxycorticosterone; D000450:Aldosterone; D012964:Sodium; D006854:Hydrocortisone; D008797:Metyrapone